Unknown

Dataset Information

0

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.


ABSTRACT: BACKGROUND:To identify factors for starting biosimilar TNF inhibitors (TNFI) in patients with rheumatic diseases. METHODS AND FINDING:Using a national claims database, we identified patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) who had used TNFIs since they were approved in Korea in 2004. We assessed changes in the proportion of each form of TNFI used between 2004 and 2017. We then selected patients starting on TNFIs between 2013 and 2017 to identify factors for starting biosimilars. In RA (n = 4,216), biosimilars were more likely to be initiated in clinics [odds ratio (OR) 2.54] and in the metropolitan area (OR, 2.02), but were less likely to be initiated in general hospitals (OR 0.40) or orthopedics (OR 0.44). In AS (n = 2,338), biosimilars were common at the hospital level (OR 2.20) and tended to increase over the years (OR 1.16), but were initiated less in orthopedics (OR 0.07). In addition, RA patients were more likely to initiate biosimilars in combination with methotrexate (OR 1.37), but biosimilars were not initiated frequently by patients with higher comorbidity scores (OR 0.97) or receiving glucocorticoids (OR 0.67). The patient factors favoring biosimilar in AS use were not clear. CONCLUSIONS:In Korea, the proportion of biosimilar TNFIs has increased. Type of institution and physician specialty are more important than patient factors in affecting biosimilar use. In RA, biosimilar TNFIs tend to be initiated in combination with MTX, and are less likely to be initiated in patients taking glucocorticoids or in those with high comorbidities.

SUBMITTER: Sung YK 

PROVIDER: S-EPMC6980538 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.

Sung Yoon-Kyoung YK   Jung Sun-Young SY   Kim Hyoungyoung H   Choi Seongmi S   Im Seul Gi SG   Lee Yu Sang YS   Jang Eun Jin EJ   Cho Soo-Kyung SK  

PloS one 20200124 1


<h4>Background</h4>To identify factors for starting biosimilar TNF inhibitors (TNFI) in patients with rheumatic diseases.<h4>Methods and finding</h4>Using a national claims database, we identified patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) who had used TNFIs since they were approved in Korea in 2004. We assessed changes in the proportion of each form of TNFI used between 2004 and 2017. We then selected patients starting on TNFIs between 2013 and 2017 to identify facto  ...[more]

Similar Datasets

| S-EPMC8079600 | biostudies-literature
| S-EPMC8380597 | biostudies-literature
| S-EPMC8047872 | biostudies-literature
| S-EPMC6306844 | biostudies-literature
| S-EPMC7415263 | biostudies-literature
| S-EPMC8275858 | biostudies-literature
| S-EPMC6702587 | biostudies-literature
| S-EPMC8511713 | biostudies-literature
| S-EPMC6549706 | biostudies-literature
| S-EPMC8453765 | biostudies-literature